Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome

Higher aspirin doses may be inferior in ticagrelor-treated acute coronary syndrome (ACS) patients and reducing bleeding risk whilst maintaining antithrombotic benefits could improve outcomes. We characterized the pharmacodynamics of a novel dual-antiplatelet-therapy regimen consisting of very-low-do...

Celý popis

Podrobná bibliografie

Hlavní autoři:	William A.E. Parker, Rachel C. Orme, Jessica Hanson, Hannah M. Stokes, Claire M. Bridge, Patricia A. Shaw, Wael Sumaya, Kirstie Thorneycroft, Giovanna Petrucci, Benedetta Porro, Heather M. Judge, Ramzi A. Ajjan, Bianca Rocca, Robert F. Storey
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2019-02-01
Edice:	Platelets
Témata:	aspirin bleeding p2y12 inhibitors thromboxane ticagrelor
On-line přístup:	http://dx.doi.org/10.1080/09537104.2019.1572880
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!